Filter results
You can narrow down the results using the filters
Topics
Our work
Diseases
11455 results
-
National Dust Disease Taskforce communique – 1 August 2019
This communique summarises the first meeting of the National Dust Disease Taskforce, held on 1 August 2019. -
National Dust Disease Taskforce – Terms of reference
This document contains the terms of reference for the National Dust Disease Taskforce. -
Quality Use of Pathology Program (QUPP) – Final report for the development of a mass spectrometry technical quality assurance program
This final report outlines the results of the Royal College of Pathologists of Australasia Quality Assurance Programs project to develop a development of a mass spectrometry technical quality assurance program for detecting human disease-associated proteins (Proteomics). -
Smallpox – Laboratory case definition
The Public Health Laboratory Network (PHLN) has developed standard case definitions for the diagnosis of key diseases in Australia. This document contains the laboratory case definition for smallpox. -
The Good Practice Guide: Supporting healthy eating and drinking at school
This guide was originally created and published by the Council of Australian Governments (COAG) Health Council in 2019. It provides advice for supporting healthy eating and drinking at school. -
Practice Incentives Program – Quality improvement measures
This document explains quality improvement measures for general practice under the Practice Incentives Program (PIP) Quality Improvement (QI) Incentive. -
Practice Incentives Program Quality Improvement Incentive – Frequently asked questions
This document covers frequently asked questions by general practices about how the Practice Incentives Program (PIP) Quality Improvement (QI) Incentive works. -
Taskforce final report – Diagnostic Imaging Clinical Committee
This report contains the Medicare Benefits Schedule (MBS) Review Taskforce's findings and recommendations to the Australian Government on its review of Diagnostic Imaging MBS items. -
AISR fortnightly report no. 6 – 1 July to 14 July 2019
The fortnightly Australian Influenza Surveillance Report (AISR) includes information about influenza activity, severity, impact, at-risk populations, virology, and vaccine match and effectiveness. It also gives year-to-date data and comparisons. -
Terms of Reference for Inquiry into Earle Haven Retirement Village
Terms of reference for an independent inquiry into the events surrounding the forced relocation of residents at the Earle Haven Retirement Village. -
ATAGI advice on the use of Dengvaxia® for Australians
This resource provides advice for immunisation providers regarding the administration of Dengvaxia® for Australians.
-
Eighth National HIV Strategy 2018–2022
This strategy is 1 of 5 national strategies that provide a framework for a high-quality and coordinated national response to bloodborne viruses (BBV) and sexually transmissible infections (STI) in Australia. -
Fifth National Aboriginal and Torres Strait Islander Bloodborne Viruses and Sexually Transmissible Infections Strategy 2018–2022
This strategy is 1 of 5 national strategies that provide a framework for a high-quality and coordinated national response to bloodborne viruses (BBV) and sexually transmissible infections (STI) in Australia. -
Fifth National Hepatitis C Strategy 2018–2022
This strategy is 1 of 5 national strategies that provide a framework for a high-quality and coordinated national response to bloodborne viruses (BBV) and sexually transmissible infections (STI) in Australia. -
Fourth National Sexually Transmissible Infections Strategy 2018–2022
This strategy is 1 of 5 national strategies that provide a framework for a high-quality and coordinated national response to bloodborne viruses (BBV) and sexually transmissible infections (STI) in Australia. -
Third National Hepatitis B Strategy 2018–2022
This strategy is 1 of 5 national strategies that provide a framework for a high-quality and coordinated national response to bloodborne viruses (BBV) and sexually transmissible infections (STI) in Australia. -
Modified Monash Model (MMM) Suburb and Locality Classification – Home Care Subsidy
Eligibility for the viability supplement is based on the location where your home care recipient receives services. From 1 January 2017, we use the MMM suburb and locality classification. -
Australian Brain Cancer Research Roadmap
This Roadmap outlines the investment strategy, rationale and implementation of the Australian Brain Cancer Mission. -
BreastScreen Australia – Current projects and activities
We provide funding for a variety of breast screening research projects and activities. Find out what current projects and activities are underway. -
Home Care Pricing Schedule Example
As a home care provider, you must include your prices for common Home Care Package services in a pricing schedule. This example shows what’s included in the schedule. You must include a copy of the schedule in all home care agreements. -
Outcomes of the Commonwealth Home Support Programme (CHSP) wellness and reablement report 2018
This report shows results of a 2018 survey of Commonwealth Home Support Programme (CHSP) service providers from all states and territories, except Victoria. -
AISR fortnightly report no. 5 – 17 June to 30 June 2019
The fortnightly Australian Influenza Surveillance Report (AISR) includes information about influenza activity, severity, impact, at-risk populations, virology, and vaccine match and effectiveness. It also gives year-to-date data and comparisons. -
Aged Care Diversity Framework action plans
This collection includes action plans to address the needs of older Aboriginal and Torres Strait Islander peoples, senior Australians from CALD backgrounds and LGBTI elders. It also includes a government action plan and a shared action plan which outlines actions to support all diverse groups. -
Life Saving Drugs Program – Paroxysmal nocturnal haemoglobinuria – Medicines review protocol
This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for paroxysmal nocturnal haemoglobinuria. -
Life Saving Drugs Program – Pompe disease – Medicines review protocol
This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for Pompe disease.